# Enhanced Acute Decompensated Heart Failure â€“ RRT Protocol with HFpEF Integration

**Primary Guidelines:** 
- 2024 AHA/ACC/HFSA Heart Failure Guidelines with HFpEF Focus
- 2024 ESC Heart Failure Guidelines - HFpEF Update
- UpToDate Clinical Decision Support - HFpEF Management 2025

**Official Sources:** 
- https://www.sciencedirect.com/science/article/pii/S1443950625004597
- UpToDate HFpEF Treatment Guidelines 2025

## ENHANCED MERMAID FLOWCHART WITH HFpEF INTEGRATION

~~~mermaid
graph TD
    A["ğŸ«€ Acute HF Recognition<br/>Volume Overload + Symptoms"] --> B["ğŸ“Š LVEF Assessment<br/>Echo/Prior Records"]
    
    B --> C{"ğŸ’— Ejection<br/>Fraction?"}
    
    C -->|"â‰¤40%"| D["ğŸ’” HFrEF Protocol<br/>Standard GDMT"]
    C -->|"41-49%"| E["ğŸ”„ HFmrEF Protocol<br/>Treat as HFrEF"]
    C -->|"â‰¥50%"| F["ğŸ’ HFpEF Protocol<br/>Specialized Management"]
    
    D --> G["ğŸš¨ ABC Assessment<br/>Hemodynamic Profiling"]
    E --> G
    F --> H["ğŸ” HFpEF Etiology<br/>Contributing Factors"]
    
    H --> I{"ğŸ¯ Primary<br/>HFpEF Cause?"}
    
    I -->|HYPERTENSIVE| J["ğŸ©º HTN-Mediated<br/>BP Control Priority"]
    I -->|ISCHEMIC| K["ğŸ«€ CAD-Related<br/>Revascularization Consider"]
    I -->|RESTRICTIVE| L["ğŸ§¬ Restrictive CM<br/>Specialized Workup"]
    I -->|HYPERTROPHIC| M["ğŸ’ª HCM Management<br/>Gradient Assessment"]
    I -->|INFILTRATIVE| N["ğŸ”¬ Infiltrative Disease<br/>Amyloid/Iron Studies"]
    I -->|HIGH-OUTPUT| O["âš¡ High-Output HF<br/>Underlying Cause"]
    
    G --> P{"ğŸŒ¡ï¸ Clinical<br/>Profile?"}
    
    P -->|"WARM & WET"| Q["ğŸ’§ Standard Diuresis<br/>Volume Management"]
    P -->|"COLD & WET"| R["â„ï¸ Inotropes + Gentle Diuresis<br/>Perfusion Priority"]
    P -->|"COLD & DRY"| S["ğŸ” Rule Out Other Causes<br/>Cautious Assessment"]
    P -->|"WARM & DRY"| T["âœ… GDMT Optimization<br/>Prevention Focus"]
    
    J --> U["ğŸ’Š Antihypertensive<br/>Optimization"]
    K --> V["ğŸ”„ Ischemia Management<br/>+ Volume Control"]
    L --> W["ğŸ“‹ Genetics/Biopsy<br/>Specialist Referral"]
    M --> X["âš–ï¸ Obstruction Assessment<br/>Septal Intervention"]
    N --> Y["ğŸ§ª Biomarker Studies<br/>Targeted Therapy"]
    O --> Z["ğŸ”„ Treat Underlying<br/>High-Output State"]
    
    Q --> AA["ğŸ“Š Diuretic Response<br/>Assessment"]
    R --> BB["ğŸ’ª Perfusion Monitoring<br/>Inotrope Titration"]
    S --> CC["ğŸ” Differential Diagnosis<br/>Targeted Workup"]
    T --> DD["ğŸ“ˆ NYHA Class<br/>Reassessment"]
    
    U --> EE["ğŸ¯ BP Target<br/><130/80 mmHg"]
    V --> EE
    W --> FF["ğŸ¥ Advanced HF Center<br/>Specialized Care"]
    X --> GG["ğŸ”§ Procedural Planning<br/>Septal Reduction"]
    Y --> HH["ğŸ’‰ Disease-Specific<br/>Treatment"]
    Z --> II["âš¡ High-Output<br/>Resolution"]
    
    AA --> JJ{"ğŸ’§ Volume<br/>Response?"}
    BB --> KK{"ğŸ’ª Perfusion<br/>Improved?"}
    CC --> LL["ğŸ¯ Cause-Specific<br/>Management"]
    DD --> MM["ğŸ“‹ Symptom-Based<br/>Therapy"]
    
    JJ -->|YES| NN["âœ… Continue Current<br/>Monitor Progress"]
    JJ -->|NO| OO["â¬†ï¸ Escalate Diuretics<br/>Combination Therapy"]
    KK -->|YES| NN
    KK -->|NO| PP["ğŸš¨ Advanced Support<br/>MCS Consideration"]
    
    LL --> MM
    MM --> QQ{"ğŸ“ˆ NYHA Class<br/>II-III Symptoms?"}
    
    QQ -->|YES| RR["ğŸ’Š HFpEF-Specific<br/>SGLT2i + MRA"]
    QQ -->|NO| SS["ğŸ“Š Monitoring<br/>+ Prevention"]
    
    EE --> RR
    FF --> TT["ğŸ”¬ Advanced Diagnostics<br/>+ Targeted Therapy"]
    GG --> TT
    HH --> TT
    II --> RR
    
    NN --> UU["ğŸ“‹ GDMT Optimization<br/>Based on EF"]
    OO --> VV["ğŸ¥ Intensive Management<br/>Refractory Volume"]
    PP --> WW["âš™ï¸ MCS Evaluation<br/>Advanced Options"]
    
    RR --> XX["ğŸ“Š HFpEF Response<br/>Assessment"]
    SS --> YY["ğŸ  Outpatient<br/>Management"]
    
    UU --> ZZ{"ğŸ’— EF-Based<br/>Therapy?"}
    
    ZZ -->|"HFrEF"| AAA["ğŸ’Š 4-Pillar Therapy<br/>ACE-I/ARB + BB + MRA + SGLT2i"]
    ZZ -->|"HFpEF"| XX
    
    XX --> BBB{"ğŸ¯ HFpEF Symptoms<br/>Controlled?"}
    
    BBB -->|YES| CCC["ğŸ“ˆ Monitoring<br/>+ Optimization"]
    BBB -->|NO| DDD["â¬†ï¸ Additional Therapy<br/>GLP-1 + Advanced Options"]
    
    AAA --> EEE["ğŸ“Š GDMT Monitoring<br/>+ Titration"]
    VV --> FFF["ğŸ¥ Advanced Diuretic<br/>Strategies"]
    WW --> GGG["âš™ï¸ Bridge Decisions<br/>Recovery/Transplant/LVAD"]
    
    CCC --> HHH["ğŸ  Discharge Planning<br/>HFpEF-Specific Education"]
    DDD --> III["ğŸ”„ Multimodal Approach<br/>Specialist Coordination"]
    EEE --> JJJ["ğŸ  HFrEF Discharge<br/>Close Follow-up"]
    FFF --> KKK["ğŸ“Š Intensive Monitoring<br/>Volume Management"]
    GGG --> LLL["ğŸ¥ Advanced HF Center<br/>MCS Management"]
    
    HHH --> MMM["âœ… HFpEF Protocol<br/>Complete"]
    III --> MMM
    JJJ --> NNN["âœ… HFrEF Protocol<br/>Complete"]
    YY --> MMM
    KKK --> OOO["ğŸ“Š Reassess<br/>+ Transition"]
    LLL --> PPP["âš™ï¸ Long-term<br/>MCS Management"]
    
    OOO --> MMM
    PPP --> QQQ["ğŸ¥ Final Disposition<br/>Based on Support Level"]
    
    style A fill:#ffcccc
    style F fill:#fff2cc
    style H fill:#ffe6cc
    style RR fill:#e8f5e8
    style XX fill:#f0f8ff
    style MMM fill:#ccffee
    style NNN fill:#ccffee
~~~

## COMPREHENSIVE HFpEF-INTEGRATED CARD SYSTEM

### Card 0 â€“ Enhanced HF Recognition with EF Assessment (Node A â†’ B)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ«€ ACUTE HEART FAILURE WITH EF FOCUS    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š **Immediate LVEF determination**:    â”‚
â”‚ â€¢  Recent echo (within 12 months)       â”‚
â”‚ â€¢  Point-of-care echo if available      â”‚
â”‚ â€¢  Prior cardiac imaging                â”‚
â”‚ â€¢  Clinical records review              â”‚
â”‚                                         â”‚
â”‚ ğŸ¯ **EF-based initial classification**: â”‚
â”‚ â€¢  **HFrEF (â‰¤40%)**: Standard protocol  â”‚
â”‚ â€¢  **HFmrEF (41-49%)**: Treat as HFrEF  â”‚
â”‚ â€¢  **HFpEF (â‰¥50%)**: Specialized approachâ”‚
â”‚                                         â”‚
â”‚ ğŸ“‹ **Recognition criteria (2025)**:     â”‚
â”‚ â€¢  Acute/worsening dyspnea              â”‚
â”‚ â€¢  Signs of volume overload             â”‚
â”‚ â€¢  Known HF with decompensation         â”‚
â”‚ â€¢  Chest pain with pulmonary edema      â”‚
â”‚                                         â”‚
â”‚ ğŸš¨ **ABC priorities remain same**:      â”‚
â”‚ â€¢  Airway: Assess for impending failure â”‚
â”‚ â€¢  Breathing: O2 to maintain SpO2 >92%  â”‚
â”‚ â€¢  Circulation: IV access, BP monitoringâ”‚
â”‚                                         â”‚
â”‚ [Next: EF-specific pathway â–¶]          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 1A â€“ Comprehensive HFpEF Etiology Assessment (Node H â†’ I)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ” HFpEF CONTRIBUTING FACTORS ANALYSIS  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **ğŸ©º Primary Contributing Factors**: â”‚
â”‚ â€¢  **Hypertension** (most common)       â”‚
â”‚ â€¢  **Aging** (physiologic changes)      â”‚
â”‚ â€¢  **Coronary heart disease**           â”‚
â”‚ â€¢  **Diabetes mellitus**                â”‚
â”‚ â€¢  **Sleep-disordered breathing**        â”‚
â”‚ â€¢  **Chronic kidney disease**           â”‚
â”‚ â€¢  **Obesity** (BMI â‰¥30)                â”‚
â”‚                                         â”‚
â”‚ **ğŸ§¬ Cardiomyopathies with Preserved EF**:â”‚
â”‚ **Restrictive Cardiomyopathy:**         â”‚
â”‚ â€¢  **Familial**: Sarcomeric mutations, TTR amyloidosisâ”‚
â”‚ â€¢  **Acquired**: AL amyloid, radiation, drugsâ”‚
â”‚                                         â”‚
â”‚ **Hypertrophic Cardiomyopathy:**        â”‚
â”‚ â€¢  **Familial**: Sarcomere gene mutationsâ”‚
â”‚ â€¢  **Metabolic**: Fabry disease, glycogen storageâ”‚
â”‚                                         â”‚
â”‚ **ğŸ«€ Structural Heart Disease**:        â”‚
â”‚ â€¢  **Valvular stenosis/regurgitation**   â”‚
â”‚ â€¢  **Pericardial disease** (constrictive)â”‚
â”‚ â€¢  **High-output states**               â”‚
â”‚                                         â”‚
â”‚ [Next: Cause-specific management â–¶]    â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 1B â€“ Advanced HFpEF Differential Diagnosis
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”¬ COMPREHENSIVE HFpEF DIFFERENTIAL      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **ğŸ§ª Infiltrative Diseases**:           â”‚
â”‚ â€¢  **Cardiac amyloidosis**: AL vs ATTR   â”‚
â”‚ â€¢  **Iron overload**: Hereditary hemochromatosisâ”‚
â”‚ â€¢  **Fabry disease**: Î±-galactosidase deficiencyâ”‚
â”‚ â€¢  **Glycogen storage disease**          â”‚
â”‚                                         â”‚
â”‚ **ğŸ”„ High-Output Heart Failure**:       â”‚
â”‚ â€¢  **Hyperthyroidism**                  â”‚
â”‚ â€¢  **Arteriovenous malformations**       â”‚
â”‚ â€¢  **Severe anemia**                    â”‚
â”‚ â€¢  **Pregnancy**                        â”‚
â”‚ â€¢  **Paget's disease**                  â”‚
â”‚                                         â”‚
â”‚ **ğŸ« Right Heart Predominant**:         â”‚
â”‚ â€¢  **Pulmonary hypertension**           â”‚
â”‚ â€¢  **ARVC** (arrhythmogenic RV cardiomyopathy)â”‚
â”‚ â€¢  **RV infarction**                    â”‚
â”‚                                         â”‚
â”‚ **âš™ï¸ Obstructive Lesions**:             â”‚
â”‚ â€¢  **Atrial myxoma**                    â”‚
â”‚ â€¢  **Pulmonary vein stenosis**          â”‚
â”‚ â€¢  **Supravalvular/subvalvular stenosis**â”‚
â”‚                                         â”‚
â”‚ **ğŸ”„ Pericardial Disease**:             â”‚
â”‚ â€¢  **Cardiac tamponade**                â”‚
â”‚ â€¢  **Constrictive pericarditis**        â”‚
â”‚ â€¢  **Effusive-constrictive disease**    â”‚
â”‚                                         â”‚
â”‚ [Next: Targeted diagnostic workup â–¶]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2A â€“ NYHA Classification Integration (Node DD â†’ MM)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“ˆ NYHA FUNCTIONAL CLASS ASSESSMENT     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **ğŸ“Š NYHA Class I (Asymptomatic)**:     â”‚
â”‚ â€¢  No limitations of physical activity   â”‚
â”‚ â€¢  â‰¥7 metabolic equivalents capacity     â”‚
â”‚ â€¢  **Management**: Prevention focus      â”‚
â”‚                                         â”‚
â”‚ **ğŸ“Š NYHA Class II (Mild Symptoms)**:   â”‚
â”‚ â€¢  Slight limitation of ordinary activityâ”‚
â”‚ â€¢  5-7 metabolic equivalents capacity    â”‚
â”‚ â€¢  **Management**: Initiate HFpEF therapyâ”‚
â”‚                                         â”‚
â”‚ **ğŸ“Š NYHA Class III (Moderate)**:       â”‚
â”‚ â€¢  Marked limitation of activity         â”‚
â”‚ â€¢  2-5 metabolic equivalents capacity    â”‚
â”‚ â€¢  **Management**: Optimize all therapiesâ”‚
â”‚                                         â”‚
â”‚ **ğŸ“Š NYHA Class IV (Severe)**:          â”‚
â”‚ â€¢  Unable to carry on physical activity  â”‚
â”‚ â€¢  <2 metabolic equivalents capacity     â”‚
â”‚ â€¢  **Management**: Advanced HF referral  â”‚
â”‚                                         â”‚
â”‚ **ğŸ¯ Metabolic Equivalent Examples**:   â”‚
â”‚ â€¢  **7 METs**: Carry 24lb up 8 steps    â”‚
â”‚ â€¢  **5 METs**: Sexual intercourse, gardeningâ”‚
â”‚ â€¢  **2 METs**: Shower, make bed, dress   â”‚
â”‚                                         â”‚
â”‚ [Next: Symptom-based therapy â–¶]        â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2B â€“ HFpEF-Specific Pharmacotherapy (Node RR â†’ XX)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’Š HFpEF-SPECIFIC MEDICATION PROTOCOL   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **ğŸ¯ SGLT2 Inhibitors (First-line)**[24][28]:â”‚
â”‚ â€¢  **Dapagliflozin**: 10mg daily (fixed dose)â”‚
â”‚ â€¢  **Empagliflozin**: 10mg daily (fixed dose)â”‚
â”‚ â€¢  **Benefits**: â†“HF hospitalization, improved QOLâ”‚
â”‚ â€¢  **Evidence**: HR 0.74 for HF events[28] â”‚
â”‚ â€¢  **Monitoring**: eGFR, volume status   â”‚
â”‚                                         â”‚
â”‚ **ğŸ§‚ Mineralocorticoid Receptor Antagonists**[25]:â”‚
â”‚ â€¢  **Spironolactone**: 12.5-25mg â†’ 25-50mg dailyâ”‚
â”‚ â€¢  **Eplerenone**: 25mg â†’ 50mg daily     â”‚
â”‚ â€¢  **Finerenone**: 20mg â†’ 40mg daily     â”‚
â”‚ â€¢  **Prerequisites**: K+ â‰¤4.7, eGFR â‰¥30  â”‚
â”‚ â€¢  **Titration**: Double dose q4 weeks   â”‚
â”‚                                         â”‚
â”‚ **â“ Limited Evidence Therapies**[27]:   â”‚
â”‚ â€¢  **Sacubitril/valsartan**: Consider if EF 50-60%â”‚
â”‚ â€¢  **ACE-I/ARBs**: For HTN/DM indicationsâ”‚
â”‚ â€¢  **Beta-blockers**: For CAD/HTN/AF    â”‚
â”‚                                         â”‚
â”‚ **ğŸš« Ineffective in HFpEF**[22]**:      â”‚
â”‚ â€¢  Nitrates (may â†“activity tolerance)    â”‚
â”‚ â€¢  Phosphodiesterase-5 inhibitors       â”‚
â”‚ â€¢  Digoxin (no benefit demonstrated)    â”‚
â”‚                                         â”‚
â”‚ [Next: Response assessment â–¶]          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3A â€“ Enhanced Loop Diuretic Dosing (Based on UpToDate Guidelines)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’§ EVIDENCE-BASED LOOP DIURETIC DOSING  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **ğŸ“Š Heart Failure Dosing (mg)**:       â”‚
â”‚                                         â”‚
â”‚ | Drug | Starting | Max Effective | Max Daily |â”‚
â”‚ |------|----------|---------------|-----------|â”‚
â”‚ |Furosemide|20 BID|80 TID|600|     â”‚
â”‚ |Bumetanide|0.5 BID|3 TID|10|      â”‚
â”‚ |Torsemide|10 daily|50 BID|200|    â”‚
â”‚                                         â”‚
â”‚ **ğŸ¯ Dosing Principles**:               â”‚
â”‚ â€¢  **2.5Ã— home dose** for IV conversion  â”‚
â”‚ â€¢  **Diuretic-naive**: Start with lowest doseâ”‚
â”‚ â€¢  **Max effective dose**: Higher doses unlikely to improve diuresisâ”‚
â”‚ â€¢  **Bioavailability**: Torsemide >80%, Furosemide ~50%â”‚
â”‚                                         â”‚
â”‚ **âš ï¸ Special Populations**:             â”‚
â”‚ â€¢  **CKD**: Higher starting doses needed â”‚
â”‚ â€¢  **Cirrhosis**: Lower max daily doses  â”‚
â”‚ â€¢  **Nephrotic syndrome**: Standard dosingâ”‚
â”‚ â€¢  **AKI**: Higher starting doses        â”‚
â”‚                                         â”‚
â”‚ [Next: Diuretic response monitoring â–¶] â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3B â€“ HFrEF Four-Pillar Therapy (Node AAA â†’ EEE)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’Š HFrEF FOUR-PILLAR OPTIMIZATION       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **ğŸ›ï¸ Pillar 1: RAS Inhibition**:        â”‚
â”‚ **Preferred**: Sacubitril/valsartan     â”‚
â”‚ â€¢  **Initial**: 24/26-49/51mg BID        â”‚
â”‚ â€¢  **Target**: 97/103mg BID              â”‚
â”‚ â€¢  **Alternative**: Lisinopril 2.5â†’40mg  â”‚
â”‚                                         â”‚
â”‚ **ğŸ›ï¸ Pillar 2: Beta-Blockers**:         â”‚
â”‚ **Preferred**: Carvedilol              â”‚
â”‚ â€¢  **Initial**: 3.125mg BID             â”‚
â”‚ â€¢  **Target**: 25mg BID (<85kg), 50mg BID (>85kg)â”‚
â”‚ â€¢  **Alternative**: Metoprolol succinate â”‚
â”‚                                         â”‚
â”‚ **ğŸ›ï¸ Pillar 3: MRA**:                   â”‚
â”‚ **Preferred**: Spironolactone          â”‚
â”‚ â€¢  **Initial**: 12.5-25mg daily         â”‚
â”‚ â€¢  **Target**: 25-50mg daily            â”‚
â”‚ â€¢  **Monitor**: K+, Cr q1-2 weeks initiallyâ”‚
â”‚                                         â”‚
â”‚ **ğŸ›ï¸ Pillar 4: SGLT2 Inhibitors**:      â”‚
â”‚ **Preferred**: Dapagliflozin 10mg daily â”‚
â”‚ â€¢  **Independent of DM status**          â”‚
â”‚ â€¢  **Can start in hospital**            â”‚
â”‚ â€¢  **Monitor**: Volume status, eGFR     â”‚
â”‚                                         â”‚
â”‚ [Next: GDMT monitoring â–¶]              â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4A â€“ Secondary HFrEF Therapies
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’Š SECONDARY HFrEF PHARMACOTHERAPY      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **ğŸ”„ Isosorbide Dinitrate + Hydralazine**:â”‚
â”‚ â€¢  **Initial**: 20mg/25mg TID            â”‚
â”‚ â€¢  **Target**: 40mg/100mg TID            â”‚
â”‚ â€¢  **Use**: Alternative to ARNI, additional therapyâ”‚
â”‚ â€¢  **Special**: Preferred in African Americansâ”‚
â”‚                                         â”‚
â”‚ **âš¡ Ivabradine**:                       â”‚
â”‚ â€¢  **Initial**: 2.5-5mg BID             â”‚
â”‚ â€¢  **Target**: 7.5mg BID                â”‚
â”‚ â€¢  **Use**: HR â‰¥70 on max beta-blocker   â”‚
â”‚ â€¢  **Requirement**: Sinus rhythm only    â”‚
â”‚                                         â”‚
â”‚ **ğŸ”¬ Vericiguat** (Novel):              â”‚
â”‚ â€¢  **Initial**: 2.5mg daily             â”‚
â”‚ â€¢  **Target**: 10mg daily               â”‚
â”‚ â€¢  **Use**: Persistent symptoms, rarely usedâ”‚
â”‚ â€¢  **Mechanism**: sGC stimulator        â”‚
â”‚                                         â”‚
â”‚ **ğŸ’Š Digoxin** (Limited Use):           â”‚
â”‚ â€¢  **Initial**: 0.0625-0.25mg daily     â”‚
â”‚ â€¢  **Target**: Serum level 0.5-0.8 ng/mL â”‚
â”‚ â€¢  **Use**: Symptomatic improvement only â”‚
â”‚ â€¢  **No mortality benefit**             â”‚
â”‚                                         â”‚
â”‚ [Next: Advanced therapy consideration â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 5A â€“ Advanced HFpEF Management (Node DDD â†’ III)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”„ ADVANCED HFpEF MULTIMODAL APPROACH   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **ğŸ‹ï¸ GLP-1 Receptor Agonists** (Obesity BMI â‰¥30):â”‚
â”‚ â€¢  **Semaglutide**: 0.25â†’2.4mg weekly SC â”‚
â”‚ â€¢  **Tirzepatide**: 2.5â†’15mg weekly SC   â”‚
â”‚ â€¢  **Benefits**: â†“weight, â†“HF hospitalizationâ”‚
â”‚ â€¢  **Monitor**: GI side effects, hypoglycemiaâ”‚
â”‚                                         â”‚
â”‚ **ğŸ“Š Device-Based Therapies**:          â”‚
â”‚ â€¢  **CardioMEMS**: PA pressure monitoring â”‚
â”‚ â€¢  **Interatrial shunt**: Limited evidenceâ”‚
â”‚ â€¢  **CRT**: No benefit in HFpEF          â”‚
â”‚                                         â”‚
â”‚ **ğŸ”¬ Specialized Interventions**:       â”‚
â”‚ â€¢  **Cardiac rehabilitation**: Exercise trainingâ”‚
â”‚ â€¢  **Sleep apnea treatment**: CPAP/BiPAP â”‚
â”‚ â€¢  **Dietary sodium restriction**: <2g/dayâ”‚
â”‚                                         â”‚
â”‚ **ğŸ¯ Comorbidity Management**:          â”‚
â”‚ â€¢  **Optimal BP control**: <130/80 mmHg  â”‚
â”‚ â€¢  **Diabetes management**: HbA1c <7%    â”‚
â”‚ â€¢  **OSA screening**: High prevalence    â”‚
â”‚ â€¢  **AF management**: Rate vs rhythm controlâ”‚
â”‚                                         â”‚
â”‚ [Next: Specialist coordination â–¶]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 5B â€“ Enhanced Discharge Planning (HFpEF-Specific)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ  HFpEF-SPECIFIC DISCHARGE PLANNING    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ âœ… **HFpEF Discharge Readiness**:       â”‚
â”‚ â€¢  Volume status optimized              â”‚
â”‚ â€¢  Comorbidities addressed (HTN, DM)    â”‚
â”‚ â€¢  SGLT2i Â± MRA initiated if appropriate â”‚
â”‚ â€¢  Patient education completed          â”‚
â”‚                                         â”‚
â”‚ ğŸ“š **HFpEF Patient Education**:         â”‚
â”‚ â€¢  **Different from HFrEF**: Emphasize comorbidity managementâ”‚
â”‚ â€¢  **Weight monitoring**: Daily weights  â”‚
â”‚ â€¢  **Exercise importance**: Cardiac rehab referralâ”‚
â”‚ â€¢  **Symptom recognition**: Dyspnea patternsâ”‚
â”‚                                         â”‚
â”‚ ğŸ’Š **HFpEF Medication Focus**:          â”‚
â”‚ â€¢  **SGLT2i adherence**: Independent of diabetesâ”‚
â”‚ â€¢  **BP medications**: Optimal control   â”‚
â”‚ â€¢  **Diuretic PRN**: For volume overload â”‚
â”‚ â€¢  **Avoid ineffective drugs**: Nitrates, PDE5iâ”‚
â”‚                                         â”‚
â”‚ ğŸ“ **HFpEF Follow-up Strategy**:        â”‚
â”‚ â€¢  **HF clinic**: 1-2 weeks             â”‚
â”‚ â€¢  **Cardiology**: If complex           â”‚
â”‚ â€¢  **Endocrinology**: If DM present     â”‚
â”‚ â€¢  **Sleep medicine**: If OSA suspected  â”‚
â”‚                                         â”‚
â”‚ [Next: Long-term HFpEF management â–¶]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 6 â€“ Integrated Quality Metrics (Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“Š COMPREHENSIVE HF QUALITY MANAGEMENT  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **ğŸ¯ EF-Specific Process Metrics**:     â”‚
â”‚ â€¢  **LVEF documentation**: >95% of cases â”‚
â”‚ â€¢  **HFrEF 4-pillar initiation**: >80%   â”‚
â”‚ â€¢  **HFpEF SGLT2i consideration**: >90%  â”‚
â”‚ â€¢  **Appropriate medication selection**: >95%â”‚
â”‚                                         â”‚
â”‚ **ğŸ“ˆ HFpEF-Specific Outcomes**:         â”‚
â”‚ â€¢  **30-day readmission**: <15%         â”‚
â”‚ â€¢  **Comorbidity optimization**: HTN <130/80â”‚
â”‚ â€¢  **Patient education completion**: >95%â”‚
â”‚ â€¢  **Cardiac rehab referral**: >80%     â”‚
â”‚                                         â”‚
â”‚ **ğŸ“Š HFrEF-Specific Outcomes**:         â”‚
â”‚ â€¢  **GDMT optimization at discharge**: >75%â”‚
â”‚ â€¢  **Beta-blocker continuation**: >90%   â”‚
â”‚ â€¢  **ARNI vs ACE-I preference**: >60%    â”‚
â”‚                                         â”‚
â”‚ **ğŸ”„ Continuous Improvement**:          â”‚
â”‚ â€¢  **Monthly EF-specific reviews**       â”‚
â”‚ â€¢  **Quarterly outcome analysis**        â”‚
â”‚ â€¢  **Annual guideline updates**         â”‚
â”‚                                         â”‚
â”‚ **ğŸ“š Staff Education**:                 â”‚
â”‚ â€¢  **HFpEF vs HFrEF differences**       â”‚
â”‚ â€¢  **New medication protocols**         â”‚
â”‚ â€¢  **Quality metric awareness**         â”‚
â”‚                                         â”‚
â”‚ âœ… **COMPREHENSIVE HF PROTOCOL COMPLETE**â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: All Treatment Pathways]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

## VIRTUA VOORHEES ENHANCED HF IMPLEMENTATION

### **HFpEF-Specific Evidence Integration (2025)**:
- **Preserved EF Recognition**: Systematic LVEF assessment with every acute HF presentation
- **Contributing Factor Analysis**: Comprehensive evaluation for hypertension, diabetes, obesity, sleep disorders
- **SGLT2 Inhibitor Priority**: First-line therapy for NYHA Class II-III HFpEF regardless of diabetes status[24][28]
- **Quality of Life Focus**: Emphasis on functional capacity improvement and symptom management

### **Advanced Diagnostic Protocols**:
- **Infiltrative Disease Screening**: Cardiac amyloidosis evaluation in appropriate patients
- **High-Output Assessment**: Thyroid function, anemia evaluation, AV malformation screening
- **Sleep Disorder Integration**: OSA screening given high prevalence in HFpEF
- **Metabolic Evaluation**: Comprehensive diabetes and obesity management

### **Technology Integration**:
- **Point-of-Care Echo**: Immediate LVEF assessment for treatment pathway selection
- **CardioMEMS Consideration**: Remote PA monitoring for selected HFpEF patients with recurrent admissions
- **Digital Health Tools**: Weight monitoring apps, medication adherence tracking
- **Telemedicine Integration**: Remote follow-up optimization for stable patients

### **Personalized Medicine Approach**:
- **Phenotype-Specific Treatment**: Hypertensive vs ischemic vs metabolic HFpEF management
- **Comorbidity-Driven Therapy**: Targeted treatment based on primary contributing factors
- **Functional Class-Based Intensity**: NYHA class-driven treatment aggressiveness
- **Patient-Centered Goals**: Quality of life and functional capacity prioritization

## REFERENCE GUIDELINES & EVIDENCE BASE
- **2024 AHA/ACC/HFSA Heart Failure Guidelines** - HFpEF Management Updates[22]
- **UpToDate Clinical Decision Support** - HFpEF Treatment Protocols 2025
- **ESC 2024 Heart Failure Guidelines** - Preserved EF Focus[24][25][28]
- **Virtua Health System Enhanced HF Protocol v2025** - EF-Integrated Management

**This comprehensive protocol represents the most advanced integration of EF-specific heart failure management, with particular emphasis on HFpEF recognition and treatment, while maintaining excellence in HFrEF care through evidence-based four-pillar therapy optimization for superior patient outcomes at Virtua Voorhees.**
